Author

Jacob Anna

Institution: University of Colorado Anschutz

Observed institutions: University of Colorado Anschutz, University of Colorado Denver

OpenAlex ID: A5113060145

Brentuximab vedotin plus AVD for Hodgkin lymphoma: incidence and management of peripheral neuropathy in a multisite cohort

2023 · Jackson T. Bowers, Jacob Anna, et al. · Blood Advances · 17

Multicenter Study of Mantle Cell Lymphoma Outcomes Following First-Line Bendamustine-Rituximab and Second-Line Bruton's Tyrosine Kinase Inhibitor Therapy

2023 · Yucai Wang, Melissa C. Larson, et al. · Blood · 10

Treatment Patterns and Outcomes for Patients with Classic Hodgkin Lymphoma (cHL) and Cardiomyopathy with Low Ejection Fraction (EF): Real-World Evidence (RWE) from 16 US Academic Centers

2023 · Kaitlin Annunzio, Eric McLaughlin, et al. · Blood · 6

Large Artery Stiffening and Remodeling in an Obese Mouse Model of Human Breast Cancer: Mitigation with Intermittent Fasting

2026 · Branden Nguyen, Ravinandan Venkatasubramanian, et al. · Physiology

Mantle cell lymphoma outcomes following sequential first-line bendamustine-rituximab and second-line Bruton’s tyrosine kinase inhibitor therapy

2026 · Yucai Wang, Melissa C. Larson, et al. · Blood Cancer Journal

Brentuximab vedotin + AVD for newly diagnosed classic Hodgkin lymphoma (cHL): Incidence and management of peripheral neuropathy in a multi-institution cohort.

2023 · Jackson Bowers, Jacob Anna, et al. · Journal of Clinical Oncology

Works count: 6

Citation count: 33

H-index: 3

I10-index: 2